Clinical trials: Moderate to Severe Atopic Dermatitis
Moderate to Severe Atopic Dermatitis
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study
- Trial name
- NCT06723080
- Testing
- VC005 low dose group, VC005 high dose group
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- NCT03607422
- Testing
- Upadacitinib
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Chronic Hand Dermatitis
Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.
- Trial name
- NCT03728504
- Testing
- ASN002
- Where
- 23 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Asana BioSciences
Atopic Dermatitis
Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis
This study aims to evaluate safety, tolerance, and efficacy in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of autologous mesenchymal stem cells.
- Trial name
- NCT02888704
- Testing
- ADSTEM Inj. (Adult human mesenchymal stem cells)
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- EHL Bio Co., Ltd.
Atopic Dermatitis
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
- Trial name
- ROCKET-Ignite (NCT05398445)
- Testing
- Rocatinlimab
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Dermatitis Atopic
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab…
- Trial name
- NCT06686628
- Testing
- Amlitelimab, Midazolam, Caffeine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Sanofi
Atopic Dermatitis
Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03531957
- Testing
- ASN002
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 244 people
- Sponsor
- Asana BioSciences
Atopic Dermatitis
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADlong (NCT05916365)
- Testing
- Lebrikizumab
- Where
- 32 sites in Germany, Poland
- Volunteers
- 174 people
- Sponsor
- Almirall, S.A.
Moderate-to-severe Atopic Dermatitis
The Study of CM310 in Patients With Atopic Dermatitis
This is an open, multicenter, extension study evaluating the safety and efficacy of CM310 for long-term treatment in patients with atopic dermatitis The primary objective is to assess the long-term safety of CM310 administered in…
- Trial name
- NCT04893707
- Testing
- CM310
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the safety and tolerability of QX-453, an investigational treatment, in healthy Chinese volunteers and patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07800104
- Testing
- QX4533
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- QuantX Biosciences, Inc.
Dermatitis, Atopic, Dermatitis
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- ADhere-J (NCT04760314)
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 37 sites in Japan
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company
Moderate-to-severe Atopic Dermatitis
A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of QLS12010 Capsules in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07344051
- Testing
- QLS12010
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD)…
- Trial name
- AD Up (NCT03568318)
- Testing
- Upadacitinib, Topical corticosteroids (TCS)
- Where
- 193 sites in United States, Australia and 22 more
- Volunteers
- 1,533 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety, tolerability, and efficacy of a multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
- Trial name
- NCT06055374
- Testing
- BxC-I17e
- Sponsor
- Brexogen Inc.
Atopic Dermatitis
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen…
- Trial name
- NCT00914186
- Testing
- TS022, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Atopic Dermatitis (AD)
PRA-216 Atopic Dermatitis Safety and Efficacy Study
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
- Trial name
- NCT07810777
- Testing
- Active PRA-216
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 39 people
- Sponsor
- Prana Therapies Inc
Atopic Dermatitis
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
This was a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12 and ≤ 48 (0-72 scale).
- Trial name
- NCT02424253
- Testing
- ZPL-3893787
- Where
- 17 sites in Belgium, Germany and 2 more
- Volunteers
- 98 people
- Sponsor
- Ziarco Pharma Ltd
Eczema Atopic Dermatitis, Eczema
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
This is a Phase 2, two-stage, adaptive, 1:1 randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy, safety, and tolerability of GX-03 topical ointment in adult subjects with atopic dermatitis…
- Conditions
- Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
- Trial name
- GX-03 in AD (NCT07355075)
- Testing
- GX-03, Vehicle
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- Turn Therapeutics
Moderate to Severe Atopic Dermatitis
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
This study is a multicenter, open-label, extended study to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of SHR-1819 injection in adult subjects with moderate to severe atopic dermatitis who have previously…
- Trial name
- NCT06012812
- Testing
- SHR-1819 injection
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.